In 2022 to 2023, 64.0% of adults in England were estimated to be either overweight or living with obesity, and 26.2% were living with obesity (official England obesity profile). BMI does not directly measure central adiposity, so two people with the same BMI can have different fat distributions and cardiometabolic risk.
Body fat distribution therefore adds information beyond the bathroom scale. The body stores fat in different depots, and visceral fat around the internal organs is more strongly associated with cardiometabolic disease than subcutaneous fat stored elsewhere.
Table of Contents
- Why Body Fat Distribution Adds More Than Weight Alone
- Visceral Versus Subcutaneous Fat Explained
- Understanding Android and Gynoid Patterns
- The Clinical Risks of Central Adiposity
- How DEXA Scans Estimate Body Composition
- Strategies to Optimise Fat Distribution
Why Body Fat Distribution Adds More Than Weight Alone
A person can step on the scale, see an unchanged number and still have a meaningful change in waist size or body composition. A smaller waist may indicate less central adiposity, but a change in appearance alone does not prove that clinical risk has improved.
The official England obesity profile also shows an unequal burden. In the most deprived areas, 71.5% of adults were overweight or living with obesity and 35.9% were living with obesity, compared with 59.6% and 20.5% in the least deprived areas. Overweight including obesity was highest among adults identifying as Black, 74.8%, followed by White British, 65.3%. These population data concern BMI categories and should not be presented as direct measurements of fat distribution. A separate commercial comparison of DEXA and 3D body scanning describes how body-composition services differ from scale weight.
Weight is not the same thing as risk
The problem with weight alone is that it treats all fat as if it behaves the same. It doesn't. Visceral fat around the organs acts differently from fat under the skin, and that difference affects blood sugar control, inflammation, vascular function, and long-term mortality risk.
Practical rule: if the waist is rising while body weight stays steady, risk can still be rising too.
That's why the conversation has to move beyond “lose weight” and into “change the distribution”. A person can lose some fat from the limbs and hips without changing much on the scale, yet still improve health if the body is shedding abdominal fat and preserving lean mass. The reverse also happens. Scale weight can fall while a person loses muscle and keeps the most harmful fat in place.
For readers trying to get a clearer picture of the difference between fat loss and weight loss, a useful starting point is this fat loss vs weight loss guide. The point is simple. Losing the right kind of weight matters more than losing weight quickly.
Visceral Versus Subcutaneous Fat Explained
Two people can have similar body size and very different internal health. Fat is not one uniform tissue. Subcutaneous fat sits under the skin and is usually the part you can pinch, while visceral fat sits deeper in the abdomen, around the organs, and behaves like metabolically active tissue.
Why visceral fat is different
Subcutaneous fat is relatively inert. Visceral fat actively disrupts metabolic function. That difference matters because abdominal fat is more closely tied to inflammation, poorer glucose control, and vascular strain than fat stored just under the skin.
The clinical significance shows up in outcome data. In an observational analysis of 357,457 UK Biobank participants, a higher visceral adiposity index was associated with all-cause, cancer and cardiovascular mortality after adjustment for measured confounders (UK Biobank publication record). The index is calculated from waist circumference, BMI, triglycerides and HDL cholesterol; it is not an imaging measurement of visceral fat, and an association does not prove causation. The government obesity commentary provides population prevalence context but is not the source of those mortality estimates.
The pattern can matter even more than BMI. In one UK Biobank imaging cohort, higher VAT relative to BMI was consistently linked to type 2 diabetes and cardiovascular disease, while higher liver fat was linked to type 2 diabetes only. The practical point is straightforward. Normal-looking body size does not guarantee low metabolic risk.
What clinicians look for
The simplest clinical clue is central adiposity, especially an increasing waist measurement. Current NICE guidance advises adults with a BMI below 35 kg/m² to use waist-to-height ratio alongside BMI: 0.5 to 0.59 indicates increased central adiposity and 0.6 or more indicates high central adiposity. A practical message is to keep waist circumference below half of height. This is a screening measure, not a diagnosis or direct measurement of visceral fat.
For people who want more information than weight can provide, a DEXA guide to visceral-fat estimates explains how regional body-composition data can add context to abdominal risk. The Telomyx whole-body DEXA scan reports regional tissue estimates rather than relying on weight alone. These measurements still need interpretation alongside waist, blood pressure, blood tests and clinical history where relevant.
Understanding Android and Gynoid Patterns
Not all fat is distributed evenly, and the pattern often reflects sex hormones, age, and life stage. The classic android pattern concentrates fat around the abdomen, creating an apple shape. The gynoid pattern stores more around the hips and thighs, creating a pear shape. These patterns are not just visual descriptions, they map to different risk profiles.
Why the “apple” pattern matters
Android distribution is generally associated with greater cardiometabolic risk than gynoid distribution, especially when waist-to-height ratio is increasing. Population differences by deprivation, age and ethnicity should not be assumed to reflect fat distribution without direct evidence. The BodyView comparison provides commercial information about DEXA and 3D scanning, not an epidemiological analysis of those inequalities.
For many women, the shift becomes more obvious during perimenopause and menopause. Fat that was previously stored more peripherally can start to gather centrally, even when body weight doesn't change much. That's why so many women describe feeling “the same weight, but different shape”. Clinically, that sentence usually means the risk profile has changed.
The waistline often tells the truth before the scale does.
The UK Biobank data reinforces that point. BMI alone can miss people with excess abdominal fat, including those who look “normal weight” on paper but still carry a higher burden of heart and metabolic risk. Research cited in the UK discussion of body fat and health found that even people with a normal BMI often had excess abdominal fat linked to serious heart problems, including heart failure, atrial fibrillation, and cardiovascular death, especially among older adults and women (Mass General Brigham summary of JACC findings).
Why gynoid fat is not just “good fat”
Gynoid fat is generally associated with lower cardiometabolic risk than central fat, but that does not make any body shape automatically healthy or unhealthy. A person with more thigh and hip storage may still have low lean tissue or visceral fat, while someone with a slimmer frame can still have central adiposity.
Some women who remain active notice a larger waist in midlife without a large change in body weight. Ageing and the menopausal transition can contribute to a more central fat pattern, but individual changes also warrant consideration of activity, diet, sleep, medicines and health conditions.
The Clinical Risks of Central Adiposity
Central adiposity is a clinical risk marker, not a cosmetic detail. When fat settles around the abdomen, especially in visceral compartments, it tracks with worse cardiometabolic outcomes and greater strain on vascular and metabolic systems.
What the data says about long-term risk
UK Biobank data supports that concern. In the prospective analysis already noted earlier, higher visceral adiposity lined up with higher mortality risk from all causes, cancer, and cardiovascular causes. The practical reading is simple, excess visceral fat shifts prognosis in the wrong direction even before a person looks obviously unwell. It is a biologically active risk state, not surplus weight with no consequence.
The same UK evidence base shows that abdominal obesity has been rising and carries independent metabolic consequences. In England, abdominal obesity increased from 26.2% to 39.0% in men and from 32.4% to 47.0% in women between 1993 and 2003, and both generalized and abdominal obesity were independently associated with higher risk of hypertension, diabetes, and their co-morbidity (UK PubMed source). Waist gain is not benign just because the scale moves slowly.
How clinicians think about measurement
A tape measure still has value, and waist circumference belongs in routine practice. It screens for central risk, but it does not fully describe body composition.
For a more accurate assessment, the hierarchy is usually clear.
- Waist circumference, quick and accessible.
- BMI plus waist, better than BMI alone.
- Regional imaging or DEXA, when the goal is to see where tissue is stored.
The major error is stopping at BMI. NICE advises using waist-to-height ratio alongside BMI for adults with a BMI below 35 kg/m² because BMI is not a direct measure of central adiposity. The UK study cited above separately supports the association between abdominal obesity and hypertension or diabetes; it is not the source of the NICE recommendation.
How DEXA Scans Estimate Body Composition
DEXA gives a different answer from a scale. Instead of one number, it estimates fat mass and lean soft tissue by region and provides bone measures. It can show whether the trunk is changing differently from the limbs, although lean soft tissue is not identical to skeletal muscle.
What DEXA adds that the scale cannot
A DEXA scan can estimate whether a change in body weight is more consistent with fat or lean-tissue change and whether trunk fat is changing differently from limb fat. Some systems also estimate visceral adipose tissue from the abdominal region. Unlike CT or MRI, DEXA does not directly image and separate visceral from subcutaneous fat, so the output should be treated as an estimate (review of abdominal-fat assessment methods).
That is why scan quality matters. If you want to understand how to interpret the numbers properly, the DEXA accuracy overview is a useful place to start before using the result to guide decisions.
A DEXA-based service such as the DEXA Body Composition Scan applies that logic in practice, with regional estimates that can be compared when repeat imaging is medically justified and performed under consistent conditions. This can add context when body weight looks stable but composition may be changing.
UK regulatory note: DEXA may currently be used only for permitted medical purposes, with each exposure individually justified. The UK government position published 30 March 2026 states that non-medical DEXA for sports performance, fitness profiling or general body composition is prohibited.
Why this matters for real-world tracking
Where repeat imaging is medically indicated and individually justified, DEXA can support trend tracking when scans use the same device and consistent preparation. A scan showing increased lean soft tissue and lower trunk fat may support the interpretation that body composition is improving, while a fall in both body weight and lean soft tissue warrants reviewing the wider plan.
That is the clinical value of the method. It gives practitioners a way to judge whether a person is losing the right tissue, not just losing mass.
- If BMI is high, DEXA can distinguish estimated fat mass from lean soft tissue.
- If BMI is in the healthy range, regional DEXA estimates can add context about abdominal fat.
- If repeat DEXA is medically indicated, it can help assess changes in tissue compartments.
The Telomyx model uses a mobile clinic setup, which can reduce the practical barriers to medically indicated testing. The SUSTAIN Body Composition Test Bundle includes repeat-test credits managed through the booking platform. Each DEXA exposure still requires a permitted medical purpose and fresh individual justification, so it must not be scheduled simply for routine wellness tracking.
DEXA can make body composition part of a more informed conversation. For someone trying to reduce abdominal fat while preserving lean tissue and bone health, it adds information that body weight alone cannot provide.
Strategies to Optimise Fat Distribution
Improving body composition generally means reducing excess fat while preserving lean tissue. Fat distribution is influenced by factors including age, sex hormones, genetics and overall adiposity, so no lifestyle intervention can guarantee loss from a chosen depot. Diet quality, sustainable energy balance, physical activity and resistance training can improve overall body composition and cardiometabolic health.
What tends to work
- Improve diet quality first. Whole-food eating patterns are more likely to reduce the energy surplus that favours central fat gain.
- Keep resistance training in the plan. Preserving muscle helps avoid the “lighter but softer” result where weight falls but body composition worsens.
- Use aerobic work for metabolic pressure. Cardio supports energy expenditure and glucose handling, which matters when visceral fat is the concern.
- Protect sleep and reduce chronic stress. Poor sleep and sustained stress can worsen fat distribution through appetite, insulin handling, and recovery.
- Use measurement to guide adjustments. A DEXA scan can estimate changes in regional fat, lean soft tissue and overall body composition, and some systems estimate VAT. For a closer look at how that works, see DEXA visceral fat analysis.
Consistency matters more than intensity when the goal is better tissue partitioning.
Short-term restriction often produces faster weight loss, but it can also fail to protect muscle or improve fat distribution in a useful way. A slower approach that keeps protein adequate, training regular, and sleep stable usually gives a better body-composition result. That trade-off matters for longevity, because the aim is not just a smaller body, it is a healthier one.
When someone needs more structure, a medically supervised weight-loss programme can be appropriate, especially if central adiposity accompanies insulin resistance, blood-pressure concerns or repeated difficulty with self-directed change. Medical oversight can help manage comorbidities and treatment risk, but it cannot direct fat loss to a specific body region.
Repeat body-composition testing can add context to scale and waist trends, provided the method and preparation are consistent and the change exceeds normal measurement variation.
This article is for general information and is not a diagnosis or substitute for individual medical advice. Discuss concerns about abdominal weight gain, cardiometabolic risk or weight-management treatment with an appropriately qualified healthcare professional. DEXA uses a low dose of ionising radiation and is generally avoided during pregnancy unless clinically justified.
